CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options

References

• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013-22
   PubMed Web of Science ®Google Scholar
• Garg M, Lee BE, McGarry K, et al. CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. Am J Hematol 2014. [Epub ahead of print]
   Google Scholar
• Gaur S, Padilla O, Nahleh Z. Clinical features and prognosis of CD20 negative aggressive B-cell non-Hodgkins lymphoma. Lymphoma 2013;2013:290585
   Google Scholar
• Li YJ, Li ZM, Rao HL, et al. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution. J Transl Med 2012;10:84
   Google Scholar
• Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
   PubMed Web of Science ®Google Scholar
• Maeshima AM, Taniguchi H, Fukuhara S, et al. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 2013;37:563-70
   Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20
   PubMed Web of Science ®Google Scholar
• Stein H, Harris N, Campo E. Plasmablastic lymphoma. In: Swerdlow S, Campo E, Harris N, et al. editors. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, 4th Edition. IARC, Lyon 2008;256-7
   Google Scholar
• Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95:1342-9
   PubMed Web of Science ®Google Scholar
• Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2005;18:806-15
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Furman M, Beltran BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012;118:5270-7
   PubMed Web of Science ®Google Scholar
• Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34:1686-94
   PubMed Web of Science ®Google Scholar
• Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008;83:804-9
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014;38:875-86
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk 2011;11:185-9
   PubMed Web of Science ®Google Scholar
• Liu JJ, Zhang L, Ayala E, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res 2011;35:1571-7
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010;51:2047-53
   PubMed Web of Science ®Google Scholar
• Noy A, Chadburn A, Lensing SY, Moore P. Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC). 2013;122:1801-1
   Google Scholar
• Schommers P, Wyen C, Hentrich M, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 2013;27:842-5
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Re A, Ungari M, et al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center’s experience. Leuk Lymphoma 2014. [Epub ahead of print]
   Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 2010;15:293-9
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 4.2014. AIDS-Related B-Cell Lymphomas. Available from: www.nccn.org/professionals/physician_gls/pdf/nhl.pdf [Last Accessed on 18 September 2014]
   Google Scholar
• Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01092182
   Google Scholar
• Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: a Review. Biol Blood Marrow Transplant 2014. [Epub ahead of print]
   Google Scholar
• Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010;28:e704-8
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Bauer F, Codreanu I, et al. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol 2013;31:164-6
   PubMed Web of Science ®Google Scholar
• Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol 2014;93:77-80
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol 2014; In press
   Google Scholar
• Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28:736-47
   PubMed Web of Science ®Google Scholar
• Holderness BM, Malhotra S, Levy NB, Danilov AV. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol 2013;31:e197-9
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905
   PubMed Web of Science ®Google Scholar
• Rahl PB, Lin CY, Seila AC, et al. c-Myc regulates transcriptional pause release. Cell 2010;141:432-45
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17
   PubMed Web of Science ®Google Scholar
• Banks P, Warnke R. Primary effusion lymphoma. In: Jaffe E, Harris N, Stein H, et al. editors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues edition 3. IARC WHO Classification of Tumours, Lyon, France; 2001:179-80
   Google Scholar
• Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood 1989;73:792-9
   PubMed Web of Science ®Google Scholar
• Cesarman E, Chang Y, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91
   PubMed Web of Science ®Google Scholar
• Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow S, Campo E, Harris N, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th Edition. IARC, Lyon 2008;260-1
   Google Scholar
• Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol 2013;23:457-67
   PubMed Web of Science ®Google Scholar
• Wilson KS, McKenna RW, Kroft SH, et al. Primary effusion lymphomas exhibit complex and recurrent cytogenetic abnormalities. Br J Haematol 2002;116:113-21
   PubMed Web of Science ®Google Scholar
• Boulanger E, Agbalika F, Maarek O, et al. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J 2001;2:172-9
   PubMedGoogle Scholar
• Kim Y, Park CJ, Roh J, Huh J. Current concepts in primary effusion lymphoma and other effusion-based lymphomas. Korean J Pathol 2014;48:81-90
   PubMedGoogle Scholar
• Luan SL, Boulanger E, Ye H, et al. Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration. J Pathol 2010;222:166-79
   Google Scholar
• Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011;24:295-301
   Google Scholar
• Shi Y, Hou Y, Hu Q, et al.A rare case of HHV-8-positive/HIV-negative/EBV-negative primary effusion lymphoma in a renal transplant recipient. Cytopathology 2012;23:137-9
   Google Scholar
• Matsumoto Y, Nomura K, Ueda K, et al. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk Lymphoma 2005;46:415-19
   PubMed Web of Science ®Google Scholar
• Kaplan LD. Human herpesvirus-8: kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematology Am Soc Hematol Educ Program 2013;2013:103-8
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Vaccher E, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005;7:17-27
   PubMed Web of Science ®Google Scholar
• Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004;28:1401-16
   PubMed Web of Science ®Google Scholar
• Pan ZG, Zhang QY, Lu ZB, et al. Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol 2012;36:1129-40
   PubMed Web of Science ®Google Scholar
• Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003;21:3948-54
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372-80
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-8
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Shum H, Lahijani M, et al. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma 2012;53:2378-82
   PubMed Web of Science ®Google Scholar
• Simonelli C, Tedeschi R, Gloghini A, et al. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis 2005;40:1022-7
   PubMed Web of Science ®Google Scholar
• Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003;73:143-8
   PubMed Web of Science ®Google Scholar
• El-Ayass W, Yu EM, Karcher DS, Aragon-Ching JB. Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clin Lymphoma Myeloma Leuk 2012;12:144-7
   Google Scholar
• Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2012;118:3977-83
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Marini B, Rambaldi A, Suter F. Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS 2008;22:1236-7
   PubMed Web of Science ®Google Scholar
• Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006;83:328-30
   PubMed Web of Science ®Google Scholar
• Bryant A, Milliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant 2008;14:601-2
   PubMedGoogle Scholar
• Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42
   PubMed Web of Science ®Google Scholar
• An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18:1699-704
   PubMed Web of Science ®Google Scholar
• Boulanger E, Meignin V, Oksenhendler E. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol 2008;141:559-61
   PubMed Web of Science ®Google Scholar
• Bhatt S, Ashlock BM, Toomey NL, et al. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. J Clin Invest 2013;123:2616-28
   PubMed Web of Science ®Google Scholar
• Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood 2013;122:1233-42
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19:3462-73
   PubMed Web of Science ®Google Scholar
• Wang HY, Fuda FS, Chen W, Karandikar NJ. Notch1 in primary effusion lymphoma: a clinicopathological study. Mod Pathol 2010;23:773-80
   Google Scholar
• Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-6
   PubMed Web of Science ®Google Scholar
• Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97:2130-6
   PubMed Web of Science ®Google Scholar
• Issacson P, Campo E, Harris NL. Large B-cell lymphoma arising in HHV8-associated multicentric Castlemans disease. In: Swerdlow S, Campo E, Harris N, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th Edition. IARC, Lyon; 2008;258-9
   Google Scholar
• Montes-Moreno S, Montalban C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma 2012;53:185-94
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boutboul D, Beldjord K, et al. Human herpesvirus 8+ polyclonal IgMlambda B-cell lymphocytosis mimicking plasmablastic leukemia/lymphoma in HIV-infected patients. Eur J Haematol 2013;91:497-503
   Google Scholar
• Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s disease. Pathol Int 2001;51:671-9
   PubMed Web of Science ®Google Scholar
• Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16:236-46
   PubMed Web of Science ®Google Scholar
• Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347-52
   PubMed Web of Science ®Google Scholar
• Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011;136:183-94
   PubMed Web of Science ®Google Scholar
• Pagni F, Bosisio FM, Sala E, et al. The plasmablasts in Castleman disease. Am J Clin Pathol 2013;139:555-9
   Google Scholar
• Gerard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012;119:2228-33
   PubMed Web of Science ®Google Scholar
• Sarosiek KA, Cavallin LE, Bhatt S, et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA 2010;107:13069-74
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014;123:2924-33
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15:966-74
   PubMed Web of Science ®Google Scholar
• Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol 1989;71:31-6
   PubMed Web of Science ®Google Scholar
• Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95
   PubMed Web of Science ®Google Scholar
• Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483-90
   PubMed Web of Science ®Google Scholar
• Momose S, Tamaru J, Kishi H, et al. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol 2009;40:75-82
   PubMed Web of Science ®Google Scholar
• Beltran B, Castillo J, Salas R, et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2009;2:11
   PubMed Web of Science ®Google Scholar
• Sachdev R, Goel S, Gupta S, Sood N. Anaplastic lymphoma kinase (ALK) positive diffuse large B cell lymphoma in a 20 year old: a rare entity. Indian J Pathol Microbiol 2014;57:157-8
   PubMed Web of Science ®Google Scholar
• Stachurski D, Miron PM, Al-Homsi S, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3’ ALK gene insertion to chromosome 4 q22-24. Hum Pathol 2007;38:940-5
   PubMed Web of Science ®Google Scholar
• Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology Am Soc Hematol Educ Program 2013;2013:575-83
   Google Scholar
• Valera A, Colomo L, Martinez A, et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol 2013;26:1329-37
   PubMed Web of Science ®Google Scholar
• Nieborowska-Skorska M, Slupianek A, Xue L, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 2001;61:6517-23
   PubMed Web of Science ®Google Scholar
• Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-47
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med 2007;13:1341-8
   PubMedGoogle Scholar
• Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96:4319-27
   PubMed Web of Science ®Google Scholar
• Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009;27:4211-16
   PubMed Web of Science ®Google Scholar
• Cerchietti L, Damm-Welk C, Vater I, et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS ONE 2011;6:e18436
   Web of Science ®Google Scholar
• Amin HM, McDonnell TJ, Ma Y, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004;23:5426-34
   PubMed Web of Science ®Google Scholar
• Wass M, Behlendorf T, Schadlich B, et al. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol 2014;92:268-70
   PubMed Web of Science ®Google Scholar
• An Investigational Drug, Crizotinib (PF-02341066), is being studied in tumors, except non-small cell lung cancer, that are positive for anaplastic lymphoma kinase (ALK). Available from: https://clinicaltrials.gov/ct2/show/NCT01121588
   Google Scholar